Symbol | Exchange | Currency |
|---|
Gainers: ZIOPHARM Oncology ZIOP +39%, RenovoRx RNXT +17%, Sigilon Therapeutics (SGTX) +17%, Acumen Pharmaceuticals (ABOS) +15%, NeuroOne Medical Technologies...
ZIOPHARM Oncology has recovered more than a third of its value to record its biggest intraday gain since January 2015 after the company insiders made a series of...
RenovoRx RNXT +46% after receiving new 510(k) clearance for RenovoCath Delivery SystemMechel PAO (MTL) +36%
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,726.30 | 2,781.90 | 2,707.40 | -95.1 | -3.37% | 1.06M | NASDAQ | |||
| 142.65 | 144.75 | 142.38 | -2.72 | -1.87% | 47.90M | NASDAQ | |||
| 341.22 | 349.60 | 339.46 | -12.36 | -3.50% | 10.50M | NASDAQ | |||
| 383.87 | 403.14 | 376.03 | -24.97 | -6.11% | 9.97M | NASDAQ | |||
| 35.16 | 35.97 | 34.87 | +0.16 | +0.46% | 8.72M | NYSE | |||
| 22.13 | 23.78 | 21.95 | -1.13 | -4.86% | 9.56M | NASDAQ | |||
| 208.18 | 214.11 | 206.65 | -8.42 | -3.89% | 18.95M | NASDAQ | |||
| 157.94 | 161.31 | 157.17 | -4.67 | -2.87% | 375.77K | NASDAQ | |||
| 13.78 | 14.19 | 13.75 | +0.12 | +0.88% | 15.15M | NYSE | |||
| 22.52 | 22.84 | 22.25 | +0.46 | +2.09% | 10.89M | NYSE | |||
| 381.95 | 385.01 | 375.55 | -9.94 | -2.54% | 800.42K | NASDAQ | |||
| 94.37 | 97.25 | 93.42 | -1.11 | -1.16% | 1.89M | NASDAQ | |||
| 1,699.47 | 1,730.00 | 1,670.00 | -68.68 | -3.88% | 276.98K | NASDAQ | |||
| 90.18 | 91.47 | 89.11 | +1.93 | +2.19% | 1.53M | NYSE | |||
| 149.99 | 153.05 | 148.87 | -0.19 | -0.13% | 13.99M | NYSE |
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.